キリンホールディングス株式会社

Nurturing the Future of Japanese Wine in a Changing Climate As heatwaves and extreme weather events continue around the world, climate change is having a profound impact on winemaking. That is why the Kirin Group is looking ahead and rethinking about the future of winemaking, with the understanding that changing environmental conditions are becoming a new reality. At Château Mercian, we are advancing our philosophy of matching the right grape varieties to the right terroirs. At Jyonohira Vineyard in Yamanashi Prefecture, we have planted Souvignier Noir, a grape variety that maintains excellent color development even in warmer climate conditions. At the same time, we are expanding winemaking efforts in higher-altitude areas, such as Kataoka Vineyard in Nagano Prefecture. These efforts are already delivering results, with Château Mercian Kataoka 2023 receiving a Gold Medal at the International Wine Challenge 2026. In addition, the Beverage Future Research Institute of Kirin Holdings has launched joint research with RIKEN (The Institute of Physical and Chemical Research) to improve the adaptability of wine grapes to hot and dry growing environments. Guided by our commitment to CSV (Creating Shared Value), the Kirin Group is addressing the societal challenge of climate change through an integrated approach that connects viticulture, grape variety development, and research and development. By doing so, we aim to unlock new possibilities for Japanese wine and build a future where people and nature can thrive together, creating shared value even in an era of change. #Kirin #ChateauMercian #JapaneseWine #ClimateChange #Sustainability #CSV #CreatingSharedValue #Innovation #Viticulture #WineIndustry #InternationalWineChallenge2026

Kirin Group announced its consolidated financial results for the second quarter of FY2026. Across the Kirin Group, both Revenue and Business Profit exceeded the previous year's level. Supported by this strong performance, we have raised our full-year forecasts for Business Profit and profit attributable to owners of the parent. Through our dialogue with investors in the first half of the year, we have seen growing interest not only in our financial performance, but also in the growth strategy of our Health Science business and the future direction of our business portfolio. Leveraging a diverse business foundation centered on three business domains, Alcoholic Beverages, Non-alcoholic Beverages & Health Science, and Pharmaceuticals, Kirin is pursuing sustainable medium- to long-term growth and value creation. Among these, Health Science is a key driver of Kirin's future growth. By leveraging the strong business foundations of FANCL, Blackmores, and other brands, we continue to create new value while accelerating growth in this field. In addition, our agreement to acquire Jamieson Wellness as a wholly owned subsidiary will help expand growth opportunities in global markets, including North America, building on the strong business foundation we have developed across Asia and Oceania. Kirin Group will continue creating new value in the Food & Health domain and contributing to the health and well-being of consumers, both in mind and body. Learn more: https://lnkd.in/gqjnKZth

Entering the Next Growth Phase in Health Science At Investor Day 2026, the Kirin Group presented its mid- to long-term strategy for the Health Science business. Globally, people are living longer—but the gap between life expectancy and healthy life expectancy continues to widen. This has driven a structural shift toward preventative healthcare, creating one of the most significant opportunities in the health and wellness sector. Against this backdrop, Kirin’s Health Science business has reached an important milestone. Following the achievement of profitability in 2025, the business is now transitioning from a “foundation-building phase” to a “growth acceleration phase.” At the center of this transformation is Kirin Health Science International (KHSI)*. By integrating brands, R&D capabilities, consumer-centric marketing, and global supply chains, Kirin is building a scalable platform to accelerate growth across the APAC region and beyond. In addition, Kirin continues to strengthen its competitive advantage through proprietary, science-based ingredients such as L. lactis Plasma and Citicoline, combining fermentation and biotechnology expertise with strong product development capabilities. By addressing societal health challenges while driving business growth, Kirin aims to become a leading global player in preventive health. The Health Science business is now entering a new stage of growth. *Kirin Health Science International (KHSI): A new Kirin Group company established on April 1, 2026, to oversee the Group’s Health Science B2C business outside Japan. Photo: Members of the management team explaining the strategy for the Health Science business at Investor Day. From left: Toru Yoshimura, Director and Senior Executive Officer, who leads the Kirin Group’s Health Science strategy; Alastair Symington, Senior Executive Officer, CEO of Blackmores Limited and CEO of Kirin Health Science International; and Hideki Mitsuhashi, Senior Executive Officer and President, Representative Director of FANCL Corporation. Read more: https://lnkd.in/guKt_2sp

The Kirin Group launches Long-Term Vision “Innovate2035!” to drive sustainable growth and create the future of physical and mental well-being 🚀 Building on our strengths in fermentation and biotechnology, Kirin has expanded its portfolio across Alcoholic Beverages, Non-alcoholic Beverages & Health Science, and Pharmaceuticals. As the business environment rapidly evolves, we are entering our next phase of growth through “Innovate2035!”, combining growth in each domain with synergies across the Group. ■ In the Alcoholic Beverages business, we will establish a new "Technology Innovation Center" to centralize our technology strategy from R&D to commercialization, while strengthening external collaborations to drive innovative value creation. ■ In the Non-alcoholic Beverages business, we will address diverse health needs—including immune care, fat management, and heatstroke prevention—and continue to deliver new health value. ■ In the Health Science business, we will establish Kirin Health Science International to accelerate global expansion while enhancing both scale and profitability. ■ In the Pharmaceuticals business, we will combine antibody therapeutics, gene therapy, and AI to create life-changing value, while strengthening synergies with the Health Science business. ■ We target high single-digit percentage growth in EPS and ROIC of 10% or more, while advancing non-financial initiatives in Health and Well-Being, Community Engagement, the Environment, and Responsibility of Kirin Group which runs Alcoholic Beverage Businesses. As we approach our 120th anniversary in 2027, we will build on our heritage and continue creating new value in food and health. 👇 Learn more in the news release https://lnkd.in/g4nRicFe 👇 Visit Kirin’s Website https://lnkd.in/gs-RYJVt

Vitalize the world through innovation by our people and technology, as a global leader in CSV. The Kirin Group’s long-term vision “Innovate2035!” has begun 🚀 Through our founding beer business, Kirin has continued to refine its strengths in fermentation and biotechnology. In 2025, our Health Science business achieved profitability, and we are building a strong business portfolio across Alcoholic Beverages, Non-alcoholic Beverages & Health Science, and Pharmaceuticals. At the same time, the environment around Kirin is changing rapidly, driven by factors such as the evolution of AI. To continue growing for the next 100 years, we have formulated our new long-term vision “Innovate2035!”, leveraging the organizational capabilities we have built across diverse businesses and combining autonomous growth with the strength of group assets ✨ 💡 Key points of “Innovate2035!” • Create new value across Alcoholic Beverages, Non-alcoholic Beverages & Health Science, and Pharmaceuticals • Build systems to continuously generate innovation through AI and external co-creation • Continuously create seeds for major innovation through original, cutting-edge R&D • Evolve into a group that creates the future of physical and mental wellbeing Through Alcoholic Beverages, Non-alcoholic Beverages & Health Science, and Pharmaceuticals, the Kirin Group aims to evolve into an innovative group that contributes to food and health, and to lead society as a global leader in CSV. Our challenge for the next 100 years starts here. 👇 Learn more in the news release https://lnkd.in/g4nRicFe 👇 Visit Kirin’s Website https://lnkd.in/gs-RYJVt

Kirin Group has announced its FY2025 financial results. The presentation video is now available on YouTube. ▼ Watch the video here https://lnkd.in/gDkeVZiE ▼ Main topics ・Kirin Group Long-Term Vision/Our Vision for 2035 and a Clear Path towards Maximizing Corporate Value ・Plan for 2028& Financial Strategy/Our 3-year plan towards 2028 and The Financial Strategy to Drive It Forward ・Kirin Group Financial Results for FY2025 and FY2026 Forecast ▼ For more details, please visit our website https://lnkd.in/gqjnKZth